All Pharma News
Patients with hidradenitis suppurativa experienced efficacy with Cosentyx

Patients with hidradenitis suppurativa experienced efficacy with Cosentyx
GLOBENEWSWIRE
03 Feb 2023
Share Share
Novartis ties HQ raid to Cosentyx patent fight against Lilly

Novartis ties HQ raid to Cosentyx patent fight against Lilly
Angus Liu FIERCEPHARMA
26 Oct 2022
Share Share
Novartis Cosentyx shows improvements with hidradenitis suppurativa

Novartis Cosentyx shows improvements with hidradenitis suppurativa
GLOBENEWSWIRE
09 Sep 2022
Share Share
EU approves Norvatis’ Cosentyx for childhood arthritis

EU approves Norvatis’ Cosentyx for childhood arthritis
John Pinching PHARMATIMES
30 Jun 2022
Share Share
Novartis Cosentyx nabs +ve CHMP opinion for expanded use in childhood arthritis

Novartis Cosentyx nabs +ve CHMP opinion for expanded use in childhood arthritis
GLOBENEWSWIRE
20 May 2022
Share Share
Acelyrin snags $250M, licenses Affibody IL-17 asset for 3 trials

Acelyrin snags $250M, licenses Affibody IL-17 asset for 3 trials
Kyle LaHucik FIERCEBIOTECH
16 Nov 2021
Share Share
Cosentyx displays a 72 percent reduced arthritis flare risk

Cosentyx displays a 72 percent reduced arthritis flare risk
Anna Begley EUROPEANPHARMACEUTICALREVIEW
10 Nov 2021
Share Share
Novartis’ Cosentyx cuts flare risk in juvenile idiopathic arthritis trial

Novartis’ Cosentyx cuts flare risk in juvenile idiopathic arthritis trial
CLINICALTRIALSARENA
09 Nov 2021
Share Share
Key players in psoriasis offer strong support through branded digital channels

Key players in psoriasis offer strong support through branded digital channels
BIOSPECTRUM ASIA
13 Sep 2021
Share Share
NICE recommends Novartis’ Cosentyx for children with severe psoriasis

NICE recommends Novartis’ Cosentyx for children with severe psoriasis
Lucy Parsons PHARMATIMES
03 Sep 2021
Share Share